Eighty percent of tumors were invasive ductal carcinoma; 32.7% were luminal A-like, 25.1% luminal B-like, 19.4% HER2 enriched and 12.8% triple negative. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.